Sobi Inc.

Research activity includes primary myelofibrosis, post-polycythaemia vera myelofibrosis, and post-essential thrombocythaemia myelofibrosis, with attention to disease burden driven by splenomegaly, constitutional symptoms, and progressive marrow dysfunction.

• Primary myelofibrosis
• Post-polycythaemia vera myelofibrosis
• Post-essential thrombocythaemia myelofibrosis

The sponsor’s clinical focus in these disorders centres on treatment areas where symptom control and reduction of spleen enlargement are key therapeutic needs.